Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RZRezolute, Inc. logo

Rezolute, Inc. (RZLT)

NASDAQ · Currency in USD
$3.86 ▼ -0.01 (-0.13%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.86 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$3.86
Open
$3.78
Day's Range
$3.70 – $3.94
52 Week Range
$1.07 – $11.46
Volume
1,198,063
Avg. Volume
1,674,325
Market Cap
$372.86M
Beta (5Y Monthly)
0.61
PE Ratio (TTM)
--
EPS (TTM)
-$0.74
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.17

Profile: Rezolute, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
58
CEO
Nevan Charles Elam

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.18 · Revenue est. $1.12M
DateEst.Actual
Sep 24, 2026-$0.15-$0.20Miss
May 12, 2026-$0.14-$0.16Miss
Feb 12, 2026-$0.16-$0.22Miss
Nov 6, 2025-$0.27-$0.18Beat
Sep 17, 2025-$0.23-$0.26Miss
May 13, 2025-$0.22-$0.27Miss

Analyst view

Consensus price target
$9.17 ▲ +137.9%
Range $6.00 – $14.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on RZLT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.